par Hoogduijn, Martin Johannes;Rabelink, Ton Johannes;Van Der Laan, Luc J W;Dor, Frank J M F F.J.M.F.;Ijzermans, Jan J.N.M.;Genever, Paul P.G.;Lange, Claudia;Durrbach, Antoine;Houtgraaf, Jaco J.H.;Christ, Bruno;Seifert, Martina;Popp, Felix Cristoph;Shagidulin, Murat;Donckier De Donceel, Vincent 
;Deans, Robert;Ringden, Olle;Perico, Norberto;Remuzzi, Giuseppe;Bartholomew, Amelia;Schlitt, Hans Jürgen ürgen H.J.;Weimar, Willem;Baan, Carla C.C.;Grohnert, Anja;Dahlke, Marc Hendrik;Crop, Meindert Johannes;Van Rhijn, Marieke;Rowshani, Ajda Tahereh;Eggenhofer, Elke;Renner, Philipp;Reinders, Marlies E J M.E.
Référence Transplantation, 90, 2, page (124-126)
Publication Publié, 2010-07
;Deans, Robert;Ringden, Olle;Perico, Norberto;Remuzzi, Giuseppe;Bartholomew, Amelia;Schlitt, Hans Jürgen ürgen H.J.;Weimar, Willem;Baan, Carla C.C.;Grohnert, Anja;Dahlke, Marc Hendrik;Crop, Meindert Johannes;Van Rhijn, Marieke;Rowshani, Ajda Tahereh;Eggenhofer, Elke;Renner, Philipp;Reinders, Marlies E J M.E.Référence Transplantation, 90, 2, page (124-126)
Publication Publié, 2010-07
Article révisé par les pairs
| Résumé : | There is evolving interest in the use of mesenchymal stem cells (MSC) in solid organ transplantation. Pre-clinical transplantation models show efficacy of MSC in prolonging graft survival and a number of clinical studies are planned or underway. At a recent meeting of the MISOT consortium (MSC In Solid Organ Transplantation) the advances of these studies were evaluated and mechanisms underlying the potential effects of MSC discussed. Continued discussion is required for definition of safety and eventually efficacy endpoints for MSC therapy in solid organ transplantation. © 2010 by Lippincott Williams & Wilkins. |
